ES2114548T3 - Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa. - Google Patents

Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.

Info

Publication number
ES2114548T3
ES2114548T3 ES92304354T ES92304354T ES2114548T3 ES 2114548 T3 ES2114548 T3 ES 2114548T3 ES 92304354 T ES92304354 T ES 92304354T ES 92304354 T ES92304354 T ES 92304354T ES 2114548 T3 ES2114548 T3 ES 2114548T3
Authority
ES
Spain
Prior art keywords
galactosidase
beta
omega
compositions
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92304354T
Other languages
English (en)
Inventor
Mark Krevolin
David Kates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics Corp
Original Assignee
Boehringer Mannheim Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Corp filed Critical Boehringer Mannheim Corp
Application granted granted Critical
Publication of ES2114548T3 publication Critical patent/ES2114548T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE EL USO DE POLIPEPTIDOS ACEPTADOR OMEGA Y DONADOR OMEGA (QUE COMPRENDEN CERCA DE DOS TERCIOS Y UN TERCIO DEL AMINO DE MOLECULA (BETA)-GALACTOSIDASA Y TERMINOS CARBOXILO RESPECTIVAMENTE), PREPARADO POR TECNICAS DE ADN RECOMBINANTE, SINTESIS DE ADN, O TECNICAS DE SINTESIS DE POLIPEPTIDO QUIMICO, QUE SON CAPACES DE INTERACTUAR PARA FORMAR UN COMPLEJO DE ENZIMA ACTIVO CON UNA CARACTERISTICA DE ACTIVIDAD CATALITICA DE (BETA)GALACTOSIDASA, JUNTO CON METODOS MEJORADOS Y COMPOSICIONES NUEVAS PARA SISTEMAS DE COMPLEMENTACION DE ENZIMA PARA DETERMINACION CUALITATIVA Y CUANTITATIVA DE UN ANALITICO SOSPECHOSO EN UNA MUESTRA
ES92304354T 1991-05-15 1992-05-14 Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa. Expired - Lifetime ES2114548T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70054991A 1991-05-15 1991-05-15

Publications (1)

Publication Number Publication Date
ES2114548T3 true ES2114548T3 (es) 1998-06-01

Family

ID=24813926

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92304354T Expired - Lifetime ES2114548T3 (es) 1991-05-15 1992-05-14 Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.

Country Status (8)

Country Link
US (1) US5362625A (es)
EP (1) EP0514173B1 (es)
JP (1) JP2944823B2 (es)
AT (1) ATE162891T1 (es)
AU (1) AU657532B2 (es)
CA (1) CA2068190C (es)
DE (1) DE69224231T2 (es)
ES (1) ES2114548T3 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
EP0817789B1 (en) * 1996-01-26 2002-01-02 Roche Diagnostics Corporation Bis-maleimido cross-linking agents
AU783091B2 (en) * 1997-01-31 2005-09-22 Odyssey Thera, Inc. Protein fragment complementation assays to detect biomolecular interactions
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342345B1 (en) * 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
CA2205888A1 (en) * 1997-07-11 1999-01-11 John J. Priatel Complementation trap
WO1999006537A1 (en) * 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cross-linked polypeptide assay components
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
US8148110B2 (en) * 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
EP1766095B1 (en) 2004-05-18 2013-10-23 The Board of Trustees of the Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
WO2007050584A2 (en) * 2005-10-24 2007-05-03 Discoverx, Inc. Detection of intracellular enzyme complex
CN101443460B (zh) * 2006-03-13 2013-03-06 利兰·斯坦福青年大学托管委员会 利用降低亲和力酶互补报告分子***检测分子间相互作用
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
US8101373B2 (en) * 2007-10-12 2012-01-24 Discoverx Corporation β-galactosidase donor fragments
JP2014505059A (ja) 2011-01-18 2014-02-27 ジェネラル アトミクス ヒドロラーゼ酵素基質およびその使用
CA2840269C (en) 2011-06-23 2015-08-18 Discoverx Corporation Monitoring protein trafficking using beta-galactosidase reporter fragment complementation
WO2014066404A2 (en) * 2012-10-22 2014-05-01 Life Technologies Corporation System and method for visualization of optimized protein expression
CN110386986B (zh) * 2018-06-22 2024-01-26 深圳琅技生命科技有限公司 人工改造蛋白质及其构建方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378428A (en) * 1981-03-30 1983-03-29 Baker Instruments Corporation Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
US4708929A (en) * 1984-10-29 1987-11-24 Microgenics Corporation Methods for protein binding enzyme complementation assays
EP0199801B1 (en) * 1984-10-29 1993-08-25 MICROGENICS CORPORATION (a Delaware corporation) Methods for protein binding enzyme complementation assays
ES2093026T3 (es) * 1989-05-05 1996-12-16 Microgenics Corp Procedimiento de ensayo de complementacion enzimatico de enlace e proteinas.
US5244785A (en) * 1991-02-01 1993-09-14 Microgenics Corporation Determination of high molecular weight analytes using a β-galactosidase complementation assay

Also Published As

Publication number Publication date
JP2944823B2 (ja) 1999-09-06
US5362625A (en) 1994-11-08
EP0514173A2 (en) 1992-11-19
AU657532B2 (en) 1995-03-16
CA2068190C (en) 1996-12-17
EP0514173A3 (en) 1994-07-06
CA2068190A1 (en) 1992-11-16
JPH05276959A (ja) 1993-10-26
DE69224231D1 (de) 1998-03-05
ATE162891T1 (de) 1998-02-15
EP0514173B1 (en) 1998-01-28
DE69224231T2 (de) 1998-07-23
AU1629192A (en) 1993-03-11

Similar Documents

Publication Publication Date Title
ES2114548T3 (es) Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69433240D1 (de) Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
TR200100030T2 (tr) Antiviral mokrosiklik bileşikler
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
TR200003181T2 (tr) Gelişmiş çoğaltılabilirliğe sahip FAP alfa'ya özgü antikor
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
BR9810586A (pt) Peptìdio de aglutinação de integrin cìclico, composição farmacêutica que compreende o mesmo, processos para inibição e ensaio de aglutinação para identificar agentes de aglutinação de integrin
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
DK0474744T3 (da) PDGF-alfa-receptor
ES2147758T3 (es) Preparacion sinergistica para la activacion de celulas destructoras naturales.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ATE468533T1 (de) Enzym-protein-komplex
PT932689E (pt) Ensaios para homocisteina e dessulfurase de homocisteina do protozoario trichomonas vaginais
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
DE69115917D1 (de) Humane gammainterferonantagonisten
DE69426076T2 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
ATE555126T1 (de) Relaxin-chimere polypeptide und deren herstellung und anwendung
PT1186292E (pt) Preparados solidos com estrutura multinuclear
AR010333A1 (es) Una muteina ob, una secuencia de adn, un vector de expresion una celula hospedadora procariota o de mamifero, un baculovirus recombinante, una celulahospedadora, un metodo para la produccion de una muteina ob, una composicion farmaceutica, el uso de una proteina ob para la preparacion de una composi
ATE352556T1 (de) Zytomodulierende lipophile peptide zur modulation der immunsystemaktivität und hemmung von entzündungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514173

Country of ref document: ES